(Q40362914)

19 September 2017

title

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity (English)

1 reference

19 September 2017

0 references

Yellow fever 17D vaccine

1 reference

1 reference

1

Thomas P Monath

1 reference

19 September 2017

6

Douglas M Watts

1 reference

19 September 2017

Cynthia K Lee

2

1 reference

19 September 2017

Justin G Julander

3

1 reference

19 September 2017

Alicja Brown

4

1 reference

19 September 2017

David W Beasley

5

1 reference

19 September 2017

Edward Hayman

7

1 reference

19 September 2017

Patrick Guertin

8

1 reference

19 September 2017

Joseph Makowiecki

9

1 reference

19 September 2017

Joseph Crowell

10

1 reference

19 September 2017

Philip Levesque

11

1 reference

19 September 2017

Gavin C Bowick

12

1 reference

19 September 2017

Merribeth Morin

13

1 reference

19 September 2017

Elizabeth Fowler

14

1 reference

19 September 2017

Dennis W Trent

15

1 reference

19 September 2017

language of work or name

English

0 references

publication date

26 March 2010

1 reference

19 September 2017

1 reference

19 September 2017

volume

28

1 reference

19 September 2017

issue

22

1 reference

19 September 2017

page(s)

3827-3840

1 reference

Treatment of yellow fever

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

The use of yellow fever virus modified by in vitro cultivation for human immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Prevention of yellow fever in persons traveling to the tropics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Acute viscerotropic disease following vaccination against yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Viscerotropic disease following yellow fever vaccination in Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Vaccine policy changes and epidemiology of poliomyelitis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Complications of smallpox vaccination, 1968.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Phylogenetic and Evolutionary Relationships among Yellow Fever Virus Isolates in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

7 January 2021

A YELLOW FEVER VACCINE

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Pressure-inactivated yellow fever 17DD virus: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Anaphylaxis from yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

A sensitive cell-based assay for the detection of residual infectious West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

An improved method for development of toxoid vaccines and antitoxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Inactivation of DNA by beta-propiolactone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Immunogenicity of a viral model vaccine after different inactivation procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

History of thymoma and yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

A Mouse Model for Studying Viscerotropic Disease Caused by Yellow Fever Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.023

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.03.023

1 reference

19 September 2017

1 reference